You are here:

Archived: clostridium botulinum type A toxin haemagglutinin complex (Dysport®)


Following a full submission

clostridium botulinum type A toxin (Dysport®) is not recommended for use within NHS Scotland for the treatment of focal spasticity, including arm symptoms associated with focal spasticity, in conjunction with physiotherapy.

Dysport® produces a localised reduction in muscle tone in patients with post-stroke upper limb spasticity and can improve patient disability at 16 weeks. It continues to be effective after repeated administrations with no new adverse events apparent. However, patient numbers in the clinical studies were small and the benefits modest. The economic case has not been demonstrated.

Drug Details

Drug Name: clostridium botulinum type A toxin haemagglutinin complex (Dysport®)
SMC Drug ID: 353/07
Manufacturer: Ipsen Ltd
Indication: Focal spasticity
BNF Category:
Sub Category: 14.4 Vaccines and antisera
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 March 2007

Current Advice

Resubmission 14 January 2013